We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Early- and Late-onset Candidemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01406093
Recruitment Status : Completed
First Posted : July 29, 2011
Last Update Posted : December 4, 2014
Information provided by (Responsible Party):

July 28, 2011
July 29, 2011
December 4, 2014
May 2011
February 2012   (Final data collection date for primary outcome measure)
Mortality [ Time Frame: 30 days ]
Same as current
Complete list of historical versions of study NCT01406093 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Early- and Late-onset Candidemia
Early- and Late-onset Candidemia: A Retrospective Study

A timing diagnosis of candidemia is as important as the correct choice of empiric or targeted antifungal therapy. In the last years a growing body of knowledge has better characterized health-care associated (HCA) infections, which have been described in 2002 in outpatients with MRSA bloodstream infections. So far there is no compelling evidence that patients with HCA infections may develop candidemia before the usual timing of around 20-25 days after admission. Risk factors associated with HCA infections are represented by admission from long term chronic care facilities (LTCF), haemodialysis, previous admission or parenteral broad spectrum antibiotics. There are few data HCA features and early onset candidemias in the published literature.

In this proposal, the investigators aim at studying early-onset candidemia in a retrospective study in one of the largest referral hospital in Italy with a consistent range of specialties ranging (bone marrow transplant, solid organ transplant, immunosuppressed patients, ICU, complex surgery). The investigators speculate that patients with candidemia diagnosed within 10 days (early-onset) by the admission have different risk factors and prognosis of those with a late diagnosis.

Not Provided
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
The selection of patients for inclusion will be based on microbiological data (with suscesptibilty patterns of the various antifungals) extracted from the computerized archive with search for Candida spp. and "blood" either peripheral or from a central venous catheter. Candida isolated from a removed CVC tip will not be considered. The candidemia will also be defined early or late based on the time elapsed between hospital admission and diagnosis (≤ 10 days early, > 10 days late candidemia).
Not Provided
Candidemia patients
Patients with diagnosis of candidemia
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Candidemia diagnosed with positive blood culture either from a peripheral vein or CVC

Exclusion Criteria:

  • Candida isolated from a removed CVC tip will not be considered
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Giovanni Di Perri, University of Turin, Italy
Giovanni Di Perri
Merck Sharp & Dohme Corp.
Principal Investigator: Giovanni Di Perri, MD, PhD University of Turin, Italy
Study Chair: Francesco G De Rosa, MD University of Turin, Italy
University of Turin, Italy
December 2014